• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Metformin: A Promising Radiosensitizer in Neoadjuvant Rectal Cancer Treatment
CONCLUSION: Metformin might constitute a highly promising radiosensitizer in neoadjuvant LARC treatment attracting much scientific interest. Due to the lack of studies with high evidence, further advanced research is required to enhance the existing knowledge about its potential value in this field.PMID:37132307 | DOI:10.2174/1574887118666230428114349
Source: Reviews on Recent Clinical Trials - May 3, 2023 Category: Cancer & Oncology Authors: Nikolaos S Georgopoulos Maria Tolia Davide Mauri Konstantinos Kamposioras Nikolaos Charalampakis Nikolaos Tsoukalas Areti Gkantaifi Source Type: research

The Effect of Metformin on Chemotherapy-Induced Toxicities in Non-diabetic Breast Cancer Patients: A Randomised Controlled Study
CONCLUSION: Metformin offers a therapeutic opportunity for controlling toxicities caused by neoadjuvant chemotherapy in non-diabetic breast cancer patients.TRIAL REGISTRATION: This randomised controlled trial was registered on November 20, 2019 in ClinicalTrials.gov under registration number: NCT04170465.PMID:37131014 | DOI:10.1007/s40264-023-01305-4
Source: Cancer Control - May 2, 2023 Category: Cancer & Oncology Authors: Manar A Serageldin Amira B Kassem Yasser El-Kerm Maged W Helmy Mahmoud M El-Mas Noha A El-Bassiouny Source Type: research

The impact of metformin use on the outcomes of locally advanced breast cancer patients receiving neoadjuvant chemotherapy: an open-labelled randomized controlled trial
Sci Rep. 2022 May 10;12(1):7656. doi: 10.1038/s41598-022-11138-3.ABSTRACTRecently, several clinical trials have attempted to find evidence that supports the anticancer use of metformin in breast cancer (BC) patients. The current study evaluates the anticancer activity of metformin in addition to neoadjuvant chemotherapy (NACT) in locally advanced BC patients. Additionally, we assess the safety and tolerability of this combination and its effect on the quality of life (QoL) of BC patients. Eighty non-diabetic female patients with proven locally advanced BC were randomized into two arms. The first arm received anthracycline/...
Source: Cancer Control - May 10, 2022 Category: Cancer & Oncology Authors: Hadeer Ehab Barakat Raghda R S Hussein Ahmed Abdullah Elberry Mamdouh Ahmed Zaki Mamdouh Elsherbiny Ramadan Source Type: research

Efficacy of Metformin in Patients With Breast Cancer Receiving Chemotherapy or Endocrine Therapy: Systematic Review and Meta-analysis
CONCLUSION AND RELEVANCE: Metformin should be discouraged routinely in nondiabetic patients with metastatic/recurrent breast cancer. Further RCTs are needed to verify whether metformin with chemotherapy or endocrine therapy results in significant clinical benefits in the neoadjuvant or adjuvant setting.PMID:34137294 | DOI:10.1177/10600280211025792
Source: The Annals of Pharmacotherapy - June 17, 2021 Category: Drugs & Pharmacology Authors: Kayoko Morio Yasuko Kurata Nobuko Kawaguchi-Sakita Akihiro Shiroshita Yuki Kataoka Source Type: research